Mental Health & Wellness
After decades of underinvestment, mental healthcare is finally catching up to its physical counterpart — with biomarkers, digital tools, and novel therapeutics converging to tackle the world's largest disease burden.
970M
People globally affected by mental health disorders
67%
PTSD remission rate with MDMA-assisted therapy
$500B
Annual economic cost of mental illness in the US
"Let good stress do its job. Manage the bad one better."
— FOXO
Telepsychiatry & Remote Care
The pandemic forced a 10-year acceleration of telehealth in 12 months. Telepsychiatry platforms (Talkspace, BetterHelp, Cerebral, Done) now serve millions. More meaningfully, async care models — where patients message therapists between scheduled sessions — are showing equivalent outcomes to in-person CBT for mild-to-moderate depression.
Key Insight
Teletherapy increased global mental health access by 38% in 2022–2024, with the largest gains in rural and low-income populations.
Neurological Biomarkers
For the first time, blood-based biomarkers are enabling objective mental health diagnosis. Phosphorylated tau and amyloid-β predict Alzheimer's a decade before symptoms. BDNF (brain-derived neurotrophic factor) levels correlate with depression severity and antidepressant response. Multi-omic panels (proteomics + metabolomics) are building the first objective psychiatric diagnostic toolkit.
Key Insight
Alzheimer's biomarker blood tests are now 85–90% accurate — enabling treatment intervention 10+ years before cognitive decline.
Digital Mental Health Apps & CBT Tools
Woebot, Headspace Clinical, and Calm Health deploy evidence-based CBT, ACT, and mindfulness directly in the palm of your hand. While app-only care has limitations, as adjuncts to clinical care they dramatically increase dose of therapeutic intervention between sessions. The FDA has cleared several as prescription digital therapeutics for MDD and GAD.
Key Insight
Digital CBT tools reduce symptom severity in 60% of users — comparable to face-to-face therapy for mild-to-moderate cases.
Psychedelic-Assisted Therapy
MDMA-assisted therapy for PTSD and psilocybin for treatment-resistant depression are in Phase 3 FDA trials. Australia became the first country to authorise both in 2023. MAPS (Multidisciplinary Association for Psychedelic Studies) data shows 67% of PTSD patients no longer met diagnostic criteria after three MDMA sessions — extraordinary results for a condition that resists conventional pharmacotherapy.
Key Insight
67% PTSD remission rate with MDMA-assisted therapy — vs ~30% with SSRIs alone.